Online inquiry

IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4333MR)

This product GTTS-WQ4333MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL5RA gene. The antibody can be applied in Chronic Obstructive Pulmonary Disease (COPD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000564.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3568
UniProt ID Q01344
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4333MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14405MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ6059MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ10666MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-3819253
GTTS-WQ4019MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ7764MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ6041MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 136
GTTS-WQ15321MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ15988MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZTS-00521505
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW